WeLeader Biomedical Co

WeLeader Biomedical Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of WeLeader Biomedical Co (7713.TWO) as of Oct 17, 2026 is 32.43. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 30.90 — a change of 4.97% (higher).

P/FCF

32.43

YoY

4.97%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of WeLeader Biomedical Co is 2025 32.43 . P/FCF (Price-to-Free-Cash-Flow Ratio) of WeLeader Biomedical Co was 2024 30.90 . It decreases by 4.97% higher compared to the previous year.

The WeLeader Biomedical Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2020
23.97 TWD
Jan 1, 2021
15.08 TWD
Jan 1, 2022
-8.47 TWD
Jan 1, 2023
27.80 TWD
Jan 1, 2024
30.90 TWD
Jan 1, 2025
32.43 TWD
The WeLeader Biomedical Co P/FCF history
YEARP/FCFYoY
32.43+4.97%
30.90+11.14%
27.80-428.40%
-8.47-156.15%
15.08-37.08%
23.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd is a Taiwan-based company operating in the Health Care sector, specifically within Health Care Providers & Services. Headquartered in Kaohsiung, the company focuses on the agency and trading of in vitro diagnostic instruments and reagent-related products. It provides medical testing-related services, including distribution, after-sales, and maintenance for laboratory reagents, consumables, instruments, and equipment. Additionally, the company offers construction planning for medical testing laboratories, equipment procurement, operational coaching, and ancillary services such as human resources development and training. WeLeader Biomedical also develops digital medical examination platforms. The firm primarily serves the domestic market, with its products and services mainly sold within Taiwan. The company completed its initial public offering (IPO) on January 2, 2024, and is listed under the ticker symbol 7713.TWO with ISIN TW0007713000. Its website is https://www.weleader.com.tw/. The company operates in the health care industry, emphasizing diagnostic solutions and laboratory support services within Taiwan's medical infrastructure. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of WeLeader Biomedical Co is 32.43 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of WeLeader Biomedical Co changed from 30.90 to 32.43, representing a 4.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s WeLeader Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — WeLeader Biomedical Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — WeLeader Biomedical Co